First Horizon Advisors, Inc. Biocryst Pharmaceuticals Inc Transaction History
First Horizon Advisors, Inc.
- $3.58 Billion
- Q3 2024
A detailed history of First Horizon Advisors, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 688 shares of BCRX stock, worth $5,125. This represents 0.0% of its overall portfolio holdings.
Number of Shares
688
Previous 688
-0.0%
Holding current value
$5,125
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
546KPut Options Held
267K-
Vanguard Group Inc Valley Forge, PA20.3MShares$151 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$149 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$88.4 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$67.7 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$65.9 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.39B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...